New partners hope to identify targeting peptides for RNAi drugs
Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics. The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities. … Read More